Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scynexis, a drug discovery and development company, and Drugs for Neglected Diseases initiative, have extended their collaboration on vital drug discovery R&D of affordable and effective therapies for human African trypanosomiasis for an additional three years.
Subscribe to our email newsletter
The project between Scynexis and Drugs for Neglected Diseases initiative (DNDi) was initiated in 2006 and will now run through March 2012. The collaboration includes partners at Pace University networked through the HEOS software collaboration platform.
The goal of this project is to progress molecules proven to be safe and active against human African trypanosomiasis parasites in early-stage screening research through the first steps of regulatory safety assessment in the preclinical phase.
Yves Ribeill, president and CEO of Scynexis, said: “Scynexis believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases.
“We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness.”